Healthcare communication company Conversa Health revealed on Tuesday that it has appointed a new chief technology officer, Cameron Ough.
In his new role, Ough is expected to be a key leader in the continued development and implementation of a comprehensive business strategy to address opportunities in the Provider, Payer and Pharma markets. The company said Ough will establish and grow its technology roadmap and lead all the technical initiatives, focusing on customer/end-user satisfaction and value metrics for clients and partners.
Ough previously worked at Cigna for ten years, where he served as a senior director in IT, with responsibility for Clinical Data Interoperability and Consumer & Digital Health.
Earlier, Ough spent ten years at Intel in several technology initiatives as an engineering and architecture lead. He reportedly pioneered projects that included data centre management capabilities, product and service localisation. He was also the solution lead for Intel Digital Health's Remote Care Management platform.
Conversa is an intelligent, automated conversation platform for healthcare. The company has an extensive library of over 700+ clinically-intelligent conversation programs that include asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), diabetes, hypertension, and joint replacement. With its innovative and scalable Conversational AI technology, Conversa said healthcare organizations can deliver automated, personalized doctor-patient conversation experiences that lead to more meaningful patient relationships, effective population management and, ultimately, better clinical and financial outcomes.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business